Characteristics of Patients Undergoing Nd Laser Treatment at the Dermatology, Venereology, and Aesthetic Outpatient Clinic of Dr. Moewardi General Hospital, Surakarta, 2016–2025

Authors

  • Seno Lamsir Department of Dermatology and Venereology, Faculty of Medicine, Universitas Sebelas Maret Dr. Moewardi General Hospital, Surakarta
  • Arie Kusumawardhani Department of Dermatology and Venereology, Faculty of Medicine, Universitas Sebelas Maret/ Dr. Moewardi General Hospital, Surakarta
  • Alamanda Murasmita Department of Dermatology and Venereology, Faculty of Medicine, Universitas Sebelas Maret/ Dr. Moewardi General Hospital, Surakarta

DOI:

https://doi.org/10.26911/theijmed.2026.11.3.959

Abstract

Background: Nd:YAG laser is an important therapeutic modality in dermatology, venereology, and aesthetics due to its precision, effectiveness, deep tissue penetration, and favorable cosmetic outcomes. However, comprehensive data regarding patient demographics and treatment indications for Nd:YAG laser therapy in Indonesia, particularly in tertiary referral institutions, remain highly limited.Objective: To determine the characteristics of patients undergoing Nd:YAG laser therapy at the dermatology and venereology outpatient clinic of Dr. Moewardi General Hospital, Surakarta, for the period of 2016–2025.

Subject and Method: A retrospective descriptive study was conducted by analyzing secondary data from the medical records of patients who underwent Nd:YAG laser therapy. The variables examined included demographic characteristics, clinical characteristics such as diagnosis and lesion size, as well as the intensity or number of treatment sessions.

Results: A total of 172 patients underwent Nd:YAG laser procedures. Female patients (58.14%) predominated over males (41.86%). The most frequent diagnoses were nevus of Ota (18.02%), tattoo removal (8.72%), and melanocytic nevus (8.14%). Most patients required only 1–2 treatment sessions (58.72%), while 3.49% of patients required more than 15 therapy sessions

Conclusion: Nd:YAG laser therapy at Dr. Moewardi General Hospital is more frequently used for congenital dermal pigmentary disorders (melanocytosis) such as nevus of Ota compared to classic global indications like sociocultural tattoo removal. This difference emphasizes that laser practice is not only determined by global trends but is also strongly influenced by local epidemiology, modality availability, and clinician preferences.

Published

2026-06-10

Downloads

Issue

Vol.11 No.3 (2026)

Section

Articles

References

Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. (2017). 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 38(36): 2739–2791. doi:10.1093/eurheartj/ehx391.

Biteker M, Tekkeşin AI, Can MM, Dayan A, Ilhan E, Türkmen FM (2012). Out-come of noncardiac and non-vascular surgery in patients with mechanical heart valves. Am J Cardiol. 110(4): 562–567. doi:10.1016/j.amjcard.-2012.04.031.

Chan WS, Anand S, Ginsberg JS (2000). Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 160(2): 191–196. doi:10.1001/archinte.160.2.191.

Daniels PR, McBane RD, Litin SC, Ward SA, Hodge DO, Dowling NF, et al. (2009). Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. Thromb Res. 124(3): 300–305. doi:10.1016/j.thromres.20-09.01.011.

Douketis JD, Spyropoulos AC, Kaatz S, Becker RC (2012). Bridging anti-coagulation: is it needed when warfarin is interrupted around the time of a surgery or procedure? Circulation. 125(12): e496–e498. doi:10.1161/circu-lationaha.111.084517.

Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. (2012). Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 141(2): e326S–e350S. doi:10.1378/chest.11-2298.

Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, et al. (2015). Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 373(9): 823–833. doi:10.1056/NEJMoa1501035.

Eijgenraam P, ten Cate H, ten Cate-Hoek AJ (2014). The practice of bridging anticoagulation: guideline adherence and risk factors for bleeding. Neth J Med. 72(3): 157–164.

Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. (2014). 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. J Am Coll Cardiol. 64(22): e77–e137. doi:10.1016/j.jacc.2014.07.944.

Hassouna A, Allam H (2014). Limited dose warfarin throughout pregnancy in patients with mechanical heart valve prosthesis: a meta-analysis. Interact Cardiovasc Thorac Surg. 18(6): 797–806. doi:10.1093/icvts/ivu009.

Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. (2011). Guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol. 154(3): 311–324. doi:10.1111/j.1365-2141.2011.08753.x.

Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC (2012). National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 5(5): 615–621. doi:10.1161/CIRCOUTCOMES.112.967299.

Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, De Hert S, et al. (2014). 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J. 35(35): 2383–2431. doi:10.1093/eurheartj/ehu282.

Moesker MJ, de Groot JF, Damen NL, Bijsterveld NR, Twisk JWR, Huisman MV, et al. (2019). Guideline compli-ance for bridging anticoagulation use in vitamin-K antagonist patients; practice variation and factors asso-ciated with non-compliance. Thromb J. 17: 15. doi:10.1186/s12959-019-0204-x.

Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. (2014). 2014 AHA/ACC guideline for the management of patients with valvular heart disease. J Am Coll Cardiol. 63(22): e57–e185. doi:10.1016/j.jacc.2014.02.536.

Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. (2017). 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. J Am Coll Cardiol. 70(2): 252–289. doi:10.1016/j.jacc.2017.03.011.

Rechenmacher SJ, Fang JC (2015). Bridging anticoagulation: primum non nocere. J Am Coll Cardiol. 66(12): 1392–1403. doi:10.1016/j.jacc.2015.08.002.

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. (2018). 2018 ESC guidelines for the management of cardiovascular disea-ses during pregnancy. Eur Heart J. 39(34): 3165–3241. doi:10.1093/eur-heartj/ehy340.

Shaikh SI, Kumari RV, Hegade G, Maru-theesh M (2017). Perioperative consi-derations and management of patients receiving anticoagulants. Anesth Essays Res. 11(1): 10–16. doi:10.4103/0259-1162.179313.

Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC (2012). Periprocedural heparin bridging in patients receiving vitamin K anta-gonists: a systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 126: 1630–1639.

Tafur AJ, McBane R, Wysokinski WE, Litin S, Daniels P, Slusser J, et al. (2012). Predictors of major bleeding in peri-procedural anticoagulation manage-ment. J Thromb Haemost. 10(2): 261–267. doi:10.1111/j.1538-7836.2011.04572.x.

Tafur AJ, Douketis J (2018). Perioperative management of anticoagulant and antiplatelet therapy. Heart. 104(17): 1461–1467. doi:10.1136/heartjnl-2016-310581.

Tan CW, Wall M, Rosengart TK, Ghanta RK (2019). How to bridge? Management of anticoagulation in patients with mechanical heart valves undergoing noncardiac surgical procedures. J Thorac Cardiovasc Surg. 158(1): 200–203. doi:10.1016/j.jtcvs.2018.06.089.

van Hagen IM, Roos-Hesselink JW, Ruys TPE, Merz WM, Goland S, Gabriel H, et al. (2015). Pregnancy in women with a mechanical heart valve: data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation. 132(2): 132–142. doi:10.1161/circulationaha.-115.015242.

Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH (2012). Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 141(2): e576S – e600S. doi:10.1378/chest.11-2305.

Wysokinski WE, McBane RD 2nd (2012). Periprocedural bridging management of anticoagulation. Circulation. 126(4): 486–490. doi:10.1161/circu-lationaha.112.092833.

Xu Z, Fan J, Luo X, Zhang W, Ma J, Lin Y, et al. (2016). Anticoagulation regimens during pregnancy in patients with mechanical heart valves: a systematic review and meta-analysis. Can J Cardiol. 32(10): 1248.e1–1248.e9. doi:10.-1016/j.cjca.2015.11.005.